Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-935 as adjunctive therapy in pediatric Dravet syndrome and Lennox-Gastaut syndrome
CTR20182065Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of soticlestat in Dravet syndrome, Lennox-Gastaut syndrome (LGS), epilepsy, sponsored by Takeda. Started Jan 2019; status: completed.
02
Drugs
soticlestat
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)epilepsy
Beyond the preview
Go deeper on CTR20182065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182065.